Natixis Advisors LLC Sells 12,843 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Natixis Advisors LLC decreased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 27.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 33,602 shares of the medical equipment provider's stock after selling 12,843 shares during the period. Natixis Advisors LLC's holdings in Lantheus were worth $3,006,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in LNTH. Wilmington Savings Fund Society FSB acquired a new position in Lantheus during the 3rd quarter worth $25,000. Kestra Investment Management LLC acquired a new position in shares of Lantheus during the 4th quarter worth about $27,000. UMB Bank n.a. boosted its stake in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares during the period. World Investment Advisors LLC acquired a new stake in Lantheus in the 3rd quarter valued at approximately $60,000. Finally, Parkside Financial Bank & Trust grew its holdings in Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after buying an additional 280 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Down 0.5 %

NASDAQ:LNTH traded down $0.53 during mid-day trading on Tuesday, hitting $98.92. The company's stock had a trading volume of 127,229 shares, compared to its average volume of 892,157. Lantheus Holdings, Inc. has a fifty-two week low of $57.92 and a fifty-two week high of $126.89. The company has a market capitalization of $6.77 billion, a price-to-earnings ratio of 16.46 and a beta of 0.38. The stock has a fifty day moving average of $92.77 and a 200-day moving average of $96.47.

Remove Ads

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 64,109 shares of company stock valued at $6,110,806. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on LNTH shares. The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective for the company. Truist Financial increased their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. JMP Securities reaffirmed a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Finally, B. Riley decreased their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.